This category celebrates the reagents or instruments launched in the last year that are set to change the sector.

The winner of this award for 2020 is MilliporeSigma for its ZooMAb® Recombinant Antibodies, a new range of recombinant monoclonal antibodies manufactured using a proprietary expression system.

In addition, ZooMAb® Recombinant Antibodies are provided sodium azide free and lyophilized, making shipping easier and giving long term stability.

In nominating this product, the company tells us that “investing in recombinant technology allows us to more readily scale antibody production with our researchers’ needs more quickly and enables our customers to answer new questions upon the future launch of additional host species.

“In addition, the proprietary ZooMAb® antibody manufacturing process also allows us to scale up manufacturing agilely, providing greater flexibility to potential changes or demands in a researcher’s project timeline.

“Further, the development of ZooMAb® antibodies are another example of our commitment to ethical treatment of animals by reducing the involvement of host species in the antibody production process.”

Dr Andrew Chalmers, founder of CiteAb, said: “MilliporeSigma’s ZooMAb® Recombinant Antibodies are a fantastic example of an innovative product, and exactly the type of product we hoped to unearth through this award. We look forward to seeing the data for the use of this product grow, and congratulate the MilliporeSigma team on winning this award.”